<DOC>
	<DOC>NCT01756547</DOC>
	<brief_summary>Study to assess the efficacy and safety of oral potassium citrate on the Prevention of nephrocalcinosis in extreme premature: a clinical trial, randomized, double-blind placebo controlled trial.</brief_summary>
	<brief_title>Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Nephrocalcinosis</mesh_term>
	<mesh_term>Potassium Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1. Premature infants of both sexes born at the Hospital Clinic of Barcelona. 2. Corrected gestational age below 32 weeks and lower birth weight 1500gr. 3. Survivors at 7 days old. 4. Clinically stable, in the opinion of the investigator, at the time of inclusion. 5. That, properly informed, parents and / or legal guardians give written consent to allow the participation of the infant in the study and submit to the tests and examinations that it entails 1. Renal malformations, cardiac or gastrointestinal prenatal or postnatal diagnosis. 2. Chronic renal failure (serum creatinine&gt; 1.5 mg / dL or an increase of 0.3 mg / dL / day and / or oliguria defined as diuresis &lt;0.5 mL / kg / hour after the first day of life) 3. Treatment with furosemide or dexamethasone 4. Addison's disease. 5. Persistent severe metabolic alkalosis. 6. Impossibility of oral feeding.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Nephrocalcinosis</keyword>
	<keyword>Extreme premature</keyword>
</DOC>